Revenue rose 5.6% year-on-year to ₹8,853.3 crore from ₹8,382.1 crore, supported by growth across businesses. EBITDA up 0.5% to ₹₹1,801 crore from ₹1,792 crore a year earlier. EBITDA margin stood at 19.8% versus 21.4% in the year-ago period.
The company’s European business crossed €1 billion in annual revenue during FY26. Europe revenue for the quarter increased 30.2% year-on-year to ₹2,795 crore (€261 million), driven by performance across key markets. Growth Markets revenue rose 24.7% year-on-year to ₹980 crore ($107 million), while ARV revenue increased 6.4% to ₹328 crore ($36 million).
Also Read: Aurobindo Pharma to launch ₹800 crore buyback at ₹1,475 per share from April 23
Research and development expenditure, including depreciation, stood at ₹400 crore during the quarter, accounting for 4.5% of revenue. The company received final approval for nine ANDAs from the USFDA during the quarter.
The company reported a strong net cash position as of March 31, 2026, after completing payment for the acquisition of the Khandelwal Laboratories non-oncology business worth $317 million. It also said it generated free cash flows of $35 million during the quarter. Basic and diluted earnings per share stood at ₹15.86.
Formulations revenue increased 4.6% year-on-year to ₹7,646 crore. US formulations revenue declined 13% year-on-year to ₹3,543 crore due to lower transient sales and accounted for 40% of consolidated revenue.
As of March 31, 2026, the company had cumulatively filed 888 ANDAs with the USFDA and received 728 final approvals and 35 tentative approvals. The company launched 12 products during the quarter.
Also Read: Aurobindo Pharma arm gets CDSCO marketing nod for Bevqolva
Europe formulations revenue rose 30.2% year-on-year to ₹2,795 crore and contributed 31.6% of consolidated revenue. In euro terms, revenue increased 10.8% year-on-year to €261 million.
Growth Markets’ formulations revenue increased 24.7% year-on-year to ₹980 crore and accounted for 11.1% of consolidated revenue. In dollar terms, revenue rose 18.1% year-on-year to $107 million. Domestic formulation sales stood at ₹76 crore during the quarter, while FY26 revenue from the business stood at ₹302 crore.
Antiretroviral (ARV) formulations revenue rose 6.4% year-on-year to ₹328 crore, contributing 3.7% of consolidated revenue. In dollar terms, revenue increased 1% year-on-year to $36 million.
Active Pharmaceutical Ingredients (API) revenue increased 12.9% year-on-year to ₹1,208 crore and contributed 13.6% of consolidated revenue. In dollar terms, API revenue rose 6.9% year-on-year to $132 million.
K Nithyananda Reddy, Vice-Chairman and Managing Director, said, “We are encouraged by our performance for the quarter and the year, reflecting the resilience of our business model and the strength of our extensive product portfolio.
Also Read: Aurobindo Pharma arm expands MSD pact, to invest $150-175 million in new facility
Consistent volumes coupled with improved operating efficiencies and disciplined execution have contributed positively to our results. With ongoing investments in capacity expansion and the stabilisation of recently commercialised facilities, we remain confident in our ability to support sustainable growth and create long-term value for our stakeholders.”
Shares of Aurobindo Pharma Ltd ended at ₹1,546.45, up by ₹28.55, or 1.88%, on the BSE.
